ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.1429.

Several equities analysts have weighed in on PRQR shares. Zacks Research lowered ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th. Finally, Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Tuesday, November 4th.

Institutional Trading of ProQR Therapeutics

A number of institutional investors have recently modified their holdings of the business. Affinity Asset Advisors LLC lifted its position in shares of ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock worth $4,368,000 after acquiring an additional 459,512 shares in the last quarter. OneDigital Investment Advisors LLC raised its stake in shares of ProQR Therapeutics by 45.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 12,500 shares during the period. Monaco Asset Management SAM lifted its holdings in ProQR Therapeutics by 59.1% during the 1st quarter. Monaco Asset Management SAM now owns 471,908 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 175,290 shares in the last quarter. Vontobel Holding Ltd. bought a new position in ProQR Therapeutics in the 1st quarter worth about $48,000. Finally, Aberdeen Group plc purchased a new position in ProQR Therapeutics during the 1st quarter valued at about $2,461,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Stock Performance

Shares of PRQR stock opened at $2.22 on Friday. The firm has a market cap of $233.57 million, a price-to-earnings ratio of -4.72 and a beta of 0.16. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.21. The firm’s 50-day simple moving average is $2.40 and its two-hundred day simple moving average is $2.11.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The company had revenue of $3.38 million for the quarter, compared to the consensus estimate of $7.05 million. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 55.54%. Analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).